Cyclooxygenase-2 expression in invasive transitional cell carcinoma of the urinary bladder
| Autor: | Inbou Kyoku, Remi Katsuda, Hiroshi Noguchi, Nobuaki Honda, Maki Arakawa, Yoshiaki Yamada, Takaaki Hasegawa, Hiroko Saito, Yasusuke Inoue, Kogenta Nakamura, Kouji Hara, Kenji Zennami, Shigeyuki Aoki, Tomohiro Taki, Katsuya Naruse, Noriko Mitsutake, Motoi Tobiume |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Cancer Research
medicine.medical_specialty Bladder cancer Urinary bladder business.industry Urology medicine.disease Biochemistry Metastasis medicine.anatomical_structure Transitional cell carcinoma Oncology Genetics medicine Molecular Medicine Immunohistochemistry Lymph Stage (cooking) business Molecular Biology Lymph node |
| Zdroj: | Molecular medicine reports. 1(6) |
| ISSN: | 1791-2997 |
| Popis: | Cyclooxygenase-2 (COX-2) activity is reported to increase apoptosis, inhibit angiogenesis and reduce metastasis. We analyzed COX-2 expression in patients with invasive bladder cancer to evaluate the feasibility of selective COX-2 inhibitor treatment targeting COX-2. Forty patients with pathologically diagnosed invasive transitional cell carcinoma of the urinary bladder (pT2-pT4) were evaluated. Immunohistochemical staining was used to evaluate COX-2 expression, and cases with staining of ≥10% of tumor cells were defined as positive. In 2 patients, 0% of the primary tumors stained for COX-2, while 1-5% was stained in 16 patients, 5-10% in 3 patients and ≥10% in 19 patients (19/40, 47.5%). In terms of grade, 2 patients with grade 2 (2/3, 66.6%) and 17 patients with grade 3 (17/37, 45.4%) were COX-2 positive. When categorized by stage, 11 patients with pT2 (11/22, 50.0%), 6 with pT3 (6/13, 46.1%) and 2 with pT4 (2/5, 40.0%) were positive. Lymph node metastasis was observed in 10 patients; 2 of them, with pN2, were COX-2 positive. Those with COX-2-positive metastatic lymph nodes had grade 3 primary tumors, which were also COX-2 positive. In addition, COX-2-negative metastatic lymph node patients also had negative primary tumors. The results of this study suggest that 47.5% of patients with invasive bladder cancer may benefit from treatment with selective COX-2 inhibitors targeting COX-2, and that treatment efficacy can be expected in patients with lymph node metastasis when their primary tumors are COX-2 positive. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|